Shots:
- Pulse Biosciences has reported clinical data from the ablation study (n=21), an extension of the initial feasibility study, to assess the outcome durability of the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules
- Long-term follow-up showed durable efficacy with ~74% average volume reduction in treated benign thyroid nodules at 15-22mos., continued reduction was observed from 1 to 22mos., with no nodule regrowth observed
- At final follow-up, 100% of pts reported high cosmetic satisfaction & 95% were highly satisfied, with no serious AEs, & no intranodular fibrosis on ultrasound at 15-22mos.; the results were presented at the NASIT 2026
Ref: Businesswire  | Image: Pulse Biosciences  | Press Release
Related News: Pulse Biosciences Receives the US FDA IDE Approval to Initiate Study for nsPFA System in Paroxysmal Atrial Fibrillation (PAF)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
